Shionogi announced the availability of Kapvay (clonidine HCl extended-release tablets) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents ages 6–17 years old. Kapvay is indicated for use as monotherapy or for use as add-on therapy to stimulant medication.

Kapvay is available in 0.1mg and 0.2mg dosage strength tablets.

For more information call (973) 966-6900 or visit